COVID-19疫苗製造商將明年初推全新疫苗

In Market Shorts
November 29, 2021
近期非洲爆出COVID-19新變種病毒Omicron,恐導致現有疫苗保護力下降。對此,COVID-19疫苗製造商迅速採取行動,表示將調整疫苗以因應新變異株,短期內就能推出對抗Omicron病毒的COVID-19疫苗。CNBC、《Barron’s》等外媒報導,輝瑞(Pfizer)與合作夥伴BioNTech 11月26日表示,正在研究疫苗對Omicron變異病毒株的抗體效果,如有必要,可在6週內調整mRNA疫苗,並在100天內開始量產出貨。輝瑞和BioNTech預計,將在兩週內取得更多實驗室測試資料,決定是否需要針對Omicron病毒來調整疫苗。其他藥廠包括嬌生(Johnson & Johnson)、阿斯特捷利康(AstraZeneca)及莫德納(Moderna)也表示,已密切監測新出現的突變病毒,並正在測試旗下現有疫苗對最新變異株Omicron的有效性。

場外式黃金/白銀交易的風險:
Service relating to Over-the-counter (OTC) Gold Bullion/Silver trading is provided by MOL. OTC Gold/Silver Bullion trading carries a high degree of risk and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. OTC Gold/Silver Bullion is not regulated by the Securities and Futures Commission (""SFC"") and therefore trading OTC Gold/Silver Bullion will not be subject to rules or regulations promulgated by the SFC. Before deciding to trade OTC Gold/Silver Bullion you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain losses in excess of your deposited fund or even more in extreme circumstances and therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading OTC Gold/Silver Bullion, and seek advice from an independent financial advisor if you require.